Stem Cells therapy in stroke (Lakwa) patients.
- Conditions
- Health Condition 1: I60-I69- Cerebrovascular diseases
- Registration Number
- CTRI/2024/05/067029
- Lead Sponsor
- Indian Council of Medical Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients diagnosed with ischemic stroke within 1.5 months to 1 year of index event
2. Age:18-65 years
3. MRC of hand and wrist muscles between 1-3.
4. Brunnstrom stage (3-5)
5. Subjects/ care givers agreed in writing that they will be participating in clinical research, as viewed from the legal representative (patient).
1. Active Infection
2. Immunocompromised state history or laboratory results indicative of any significant cardiac, endocrine, hematologic, hepatic, renal, or other disorders
3. Neoplastic diseases ; malignancy
4. Autoimmune disorders
5. Immune-compromised subjects
6. Progressive neurological worsening
7. Contraindication to MRI
8. Female patients with known pregnancy or at risk of pregnancy, positive urine pregnancy test at screening.
9. Any other reason that, in the opinion of the Principal Investigator, makes the participant
unsuitable for participation in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Therapeutic potential of autologous bone marrow derived mononuclear stem cells (BMMNC) infusion in chronic stroke. <br/ ><br>To study upregulation of growth factors (BDNF & VEGF) after BM-MNC <br/ ><br>infusion in chronic stroke.Timepoint: Baseline, 6 weeks, 24 weeks and 1 year
- Secondary Outcome Measures
Name Time Method ATimepoint: NA